TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy by Berg, Kasper Drimer et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
TRPM4 protein expression in prostate cancer: a novel tissue biomarker
associated with risk of biochemical recurrence following radical
prostatectomy
Berg, Kasper Drimer; Soldini, Davide; Jung, Maria; Dietrich, Dimo; Stephan, Carsten; Jung, Klaus;
Dietel, Manfred; Vainer, Ben; Kristiansen, Glen
Abstract: BACKGROUNDTransient receptor potential cation channel, subfamily M, member 4 (TRPM4)
messenger RNA (mRNA) has been shown to be upregulated in prostate cancer (PCa) and might be a new
promising tissue biomarker. We evaluated TRPM4 protein expression and correlated the expression level
with biochemical recurrence (BR) following radical prostatectomy (RP). MATERIAL AND METHODS
The study included 614 patients who had undergone RP. TRPM4 immunohistochemical staining was
performed on samples of benign tissue, tissue containing PIN glands and PCa tissue using a commer-
cially available polyclonal antibody. Staining intensity was recorded by two independent observers using
a four-tired semi-quantitative grading system (0, 1+, 2+, 3+) converted into H-scores. Interobserver
agreement was calculated by linear weighted kappa statistics. The association between staining intensity
and BR was analysed using the Kaplan-Meier estimator and uni- and multiple Cox proportional hazard
regression models. RESULTS Significantly higher staining intensity was found in PCa glands compared
to benign glands (p < 0.001). The concordance rate in TRPM4 staining intensities for benign, PIN and
PCa tissue ranged from 86.0 to 91.5 %, corresponding to linear weighted kappa values of 0.566-0.789.
After adjusting for patient and tumour characteristics, patients with a higher staining intensity in PCa
glands compared to matched benign glands and an H-score equal to or above the median had an in-
creased risk of BR (HR 1.79-2.62; p = 0.01-0.03 for the two observers) when compared to patients with a
lower staining intensity. CONCLUSIONS TRPM4 protein expression is widely expressed in benign and
cancerous prostate tissue, with highest staining intensities found in PCa. Overexpression of TRPM4 in
PCa (combination of high staining intensity and a high H-score) is associated with increased risk of BR
after RP.
DOI: https://doi.org/10.1007/s00428-015-1880-y
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-124031
Akzeptierte Version
Originally published at:
Berg, Kasper Drimer; Soldini, Davide; Jung, Maria; Dietrich, Dimo; Stephan, Carsten; Jung, Klaus;
Dietel, Manfred; Vainer, Ben; Kristiansen, Glen (2016). TRPM4 protein expression in prostate cancer:
a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy.
Virchows Archiv, 468(3):345-355.
DOI: https://doi.org/10.1007/s00428-015-1880-y
ORIGINAL ARTICLE
TRPM4 protein expression in prostate cancer: a novel tissue
biomarker associated with risk of biochemical recurrence
following radical prostatectomy
Kasper Drimer Berg1 & Davide Soldini2 & Maria Jung3 & Dimo Dietrich3 &
Carsten Stephan4 & Klaus Jung5 & Manfred Dietel6 & Ben Vainer7 & Glen Kristiansen3
Received: 8 April 2015 /Revised: 20 October 2015 /Accepted: 10 November 2015 /Published online: 21 November 2015
# Springer-Verlag Berlin Heidelberg 2015
Abstract
Background Transient receptor potential cation channel, sub-
family M, member 4 (TRPM4) messenger RNA (mRNA) has
been shown to be upregulated in prostate cancer (PCa) and
might be a new promising tissue biomarker. We evaluated
TRPM4 protein expression and correlated the expression level
with biochemical recurrence (BR) following radical prostatec-
tomy (RP).
Material and methods The study included 614 patients
who had undergone RP. TRPM4 immunohistochemical
staining was performed on samples of benign tissue, tis-
sue containing PIN glands and PCa tissue using a com-
mercially available polyclonal antibody. Staining intensi-
ty was recorded by two independent observers using a
four-tired semi-quantitative grading system (0, 1+, 2+,
3+) converted into H-scores. Interobserver agreement
was calculated by linear weighted kappa statistics. The
association between staining intensity and BR was
analysed using the Kaplan-Meier estimator and uni- and
multiple Cox proportional hazard regression models.
Results Significantly higher staining intensity was found in
PCa glands compared to benign glands (p<0.001). The con-
cordance rate in TRPM4 staining intensities for benign, PIN
and PCa tissue ranged from 86.0 to 91.5 %, corresponding to
linear weighted kappa values of 0.566–0.789. After adjusting
for patient and tumour characteristics, patients with a higher
staining intensity in PCa glands compared to matched benign
glands and an H-score equal to or above the median had an
increased risk of BR (HR 1.79–2.62; p=0.01–0.03 for the two
observers) when compared to patients with a lower staining
intensity.
Conclusions TRPM4 protein expression is widely expressed
in benign and cancerous prostate tissue, with highest staining
intensities found in PCa. Overexpression of TRPM4 in PCa
(combination of high staining intensity and a high H-score) is
associated with increased risk of BR after RP.
Keywords Immunohistochemistry . Interobserver variation .
Prostate cancer . Radical prostatectomy . Tissue biomarker .
TRPM4
Abbreviation
BR-free survival Biochemical recurrence free survival
Institutions at which the work was performed Institute of Pathology,
University Hospital Bonn (UKB), Bonn, Germany; Institute of Surgical
Pathology, University Hospital Zurich (USZ), Zurich, Switzerland;
Institute of Pathology, Charité University Hospital, Berlin, Germany.
Electronic supplementary material The online version of this article
(doi:10.1007/s00428-015-1880-y) contains supplementary material,
which is available to authorized users.
* Glen Kristiansen
glen.kristiansen@ukb.uni-bonn.de
1 Copenhagen Prostate Cancer Center, Department of Urology,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
2 Institute of Surgical Pathology, University Hospital Zurich (USZ),
Zurich, Switzerland
3 Institute of Pathology, University Hospital Bonn (UKB),
Sigmund-Freud-Str. 25, 53127 Bonn, Germany
4 Department of Urology, Charité University Hospital,
Berlin, Germany
5 Berlin Institute for Urologic Research, Berlin, Germany
6 Institute of Pathology, Charité University Hospital, Berlin, Germany
7 Department of Pathology, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark
Virchows Arch (2016) 468:345–355
DOI 10.1007/s00428-015-1880-y
Introduction
Prostate cancer (PCa) is the most common newly diagnosed
malignancy among men in western countries and is estimated
to be the leading cause of male cancer deaths in Europe in
2014 only surpassed by lung cancer and colorectal cancer [1].
The course of the disease varies from entirely indolent to fatal
even for organ-confined tumours [2]. Therefore, accurate and
individual risk estimates based on patient and tumour charac-
teristics are essential for treatment decisions. Although most
nomograms and risk stratifications incorporate patient and tu-
mour characteristics including prostate-specific antigen
(PSA), Gleason score (GS), and clinical or pathological tu-
mour stage (reviewed in [3]), they still have limitations in
intercepting the heterogeneous course of the disease.
Therefore, it is of utmost importance to identify sensitive
and specific tissue, serum and urine biomarkers if the concept
of personalised medicine is to become everyday clinical prac-
tice [4].
A novel group of tissue biomarkers is the transient receptor
potential (TRP) channel superfamily. It consists of 28 cation-
permeable transmembrane channels classified into six sub-
families: TRP canonical (TRPC), TRP vanilloid (TRPV),
TRP melastatin (TRPM), TRP mucolipin (TRPML), TRP
polycystin (TRPP) and TRP ankyrin (TRPA) [5]. TRP chan-
nels are activated by a variety of mechanical and chemical
stimuli and are considered as polymodal sensors with impact
on both physiological and pathological conditions [6].
Most but not all TRP channels function as Ca2+ path-
ways, some of which are pathways for intracellular stor-
age and release of Ca2+ from various compartments
(reviewed in [7]). This can lead to alterations in intracel-
lular Ca2+-levels and subsequent increased proliferation
[8] and change in cell differentiation and apoptosis [9,
10]. As a consequence, differences in expression patterns
of TRP channels may play a role in cancer progression
[11]. The transient receptor potential cation channel, sub-
family M, member 4 (TRPM4) is a nonselective cation
channel activated by increased intracellular Ca2+ concen-
trations. Upon activation, Na+ is allowed to pass through
the channel, which, in contrast, is impermeable to Ca2+
[12]. TRPM4 is widely expressed throughout different
organs with the highest messenger RNA (mRNA) levels
found in the intestine and prostate [13]. For almost a de-
cade, it has been known that TRPM4 mRNA is upregu-
lated in PCa compared to normal tissue [14]. However,
the physiological role of TRPM4 in the prostate needs to
be further elucidated. Since our own expression data
showed overexpression of TRPM4 in PCa, and since
others have shown that knockdown of TRPM4 in HeLa
cervical cancer cells is associated with significantly de-
creased proliferation and a lower fraction of cells entering
the S-phase of the cell cycle [15], we hypothesised that
TRPM4 might also be relevant in the biology of PCa and
its expression conceivable associated with prognosis.
The aim of the present study was to confirm upregulation
of expression of TRPM4, which we had found in an earlier
study at mRNA level, at protein expression level by immuno-
histochemical (IHC) staining. Furthermore, we analysed
whether overexpression of TRPM4 protein is associated with
an increased risk of biochemical recurrence (BR) in a large
cohort of PCa patients who had undergone radical prostatec-
tomy (RP).
Materials and methods
Patient cohort
The cohort consisted of a subset of 640 PCa patients, who
underwent RP between 1999 and 2005 at the Charité
University Hospital in Berlin, Germany. Twenty-six patients
were excluded prior to this study due to missing tumour
glands in the tissue microarray (TMA) cores or insufficient
IHC staining, leaving 614 patients for analysis. The cohort
and its demographics have previously been described [16]
and are presented in short in Table 1. Clinical follow-up data
were reviewed annually. BR was defined as postoperative
PSA increase exceeding 0.2 ng/ml. The Ethics Committee of
the Charité University Hospital has approved the use of the
tissue for immunohistochemistry and molecular biological
techniques (EA1/06/2004).
Construction of the tissue microarrays
As previously described, formalin-fixed paraffin-embedded
tissue blocks from radical prostatectomy specimens were se-
lected for construction of TMA [16]. All patients were repre-
sented by five cores, which included two cores of invasive
PCa reflecting the primary and secondary Gleason pattern, if
possible. Moreover, for each patient, the TMA included one
core of benign prostatic hyperplasia (BPH), normal tissue and
prostatic intraepithelial neoplasia (PIN), respectively. If PIN
was not present in the RP specimen, another core of normal
tissue was included. All cores were 1.8 mm in diameter and
were arranged in 40 TMA recipient paraffin blocks.
Immunohistochemistry
Tissue microarray sections, each 3–4-μm thick, were mounted
on Super Frost slides (Menzel Gläser, Braunschweig,
Germany). For detection of TRPM4 expression, a commer-
cially available antibody (goat polyclonal, G-20; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA, catalogue no. sc-
27540) was diluted 1:100. The primary antibody was detected
using the refined rabbit-anti-goat protocol on the Bond
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immunohistochemistry platform (Leica). Antibody specificity
was ascertained by pre-incubation with a 10 molar excess of
its corresponding peptide (TRPM4 (G-20)P; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA, catalogue no.
sc-27540 (peptide), which nearly completely abolished immu-
noreactivity (Supplementary Fig. S1).
Assessment of immunohistochemical stainings
Two independent observers (DS+KDB), both blinded to clinical
parameters, biochemical outcomes and the scores of the other
observer, evaluated the IHC staining. A scoring sheet depicting
typical examples of staining intensities was produced after ob-
server 1 had scored the TMA slides. Observer 2 used the identi-
cal scoring sheet to enhance the interobserver agreement.
For benign, PIN and cancerous glands, the TRPM4
staining intensity was scored separately using a four-tier
semi-quantitative grading system: no staining (0), weakly
positive (1+), moderately positive (2+) and strongly pos-
itive (3+). Only plasma membrane and cytoplasmic stain-
ing were considered. Furthermore, for malignant cores,
the percentage of tumour cells expressing TRPM4 protein
with a staining intensity of 0, 1+, 2+ and 3+ was record-
ed. An H-score was derived from the semi-quantitative
estimates of the immunostaining: TRPM4-PCa H-
score=(% of cells with staining intensity 1)+2* (% of
cells with staining intensity 2+)+3*(% of cells with stain-
ing intensity 3+) [17]. Thus, the H-score range is 0 to 300,
where 0 equals all tumour cells stained negative (0),
whereas 300 equals all tumour cells stained strongly pos-
itive (3+). For interobserver statistical analyses, H-scores
were divided into four categories: low intensity (0–50),
low-moderate intensity (51–100), high-moderate intensity
(101–150) and high intensity (151–300). Furthermore, pa-
tients were dichotomised according to H-scores into ‘high
staining intensity’ (H-score equal to or above median H-
score) and ‘low staining intensity’ (H-score bellow medi-
an H-score). To also detect subtle staining intensity dif-
ferences, patients were furthermore dichotomised accord-
ing to whether TRPM4 expression was higher in PCa
g l a n d s c ompa r e d t o b e n i g n g l a n d s ( TRPM4
overexpressed vs. TRPM4 not overexpressed). Equal or
less staining intensity in PCa glands was reported as
‘TRPM4 not overexpressed’, whereas higher staining in-
tensity in PCa glands was recorded as ‘TRPM4
overexpressed’.
Statistical analysis
Associations between TRPM4 expression (high staining in-
tensity vs. low staining intensity) and demographic and clini-
cal variables were analysed using Pearson’s chi-square test for
categorical variables and the Mann-WhitneyU test for contin-
uous variables. Linear weighted Kappa statistics were used to
compare interobserver agreement and Pearson’s correlation
was calculated to compare H-scores. The Kaplan-Meier esti-
mator and log-rank tests were used to analyse the association
between TRPM4 expression levels and risk of BR following
RP. Moreover, univariate and multiple Cox proportional haz-
ard regression models were performed with BR as outcome.
Tests for linearity and proportionality were performed using
cumulative and Schoenfeld residuals under the assumption
that no interaction between covariates exists. Two-sided p-
values <0.05 were considered significant. Statistical analyses
were performed using R (R Development Core Team, Vienna,
Austria, http://www.R-project.org) and SPSS version 21
(SPSS, Armonk, NY, USA).
Results
Immunoreactivity of TRPM4 in prostate tissues
TRPM4 showed a cytoplasmic expression pattern in benign
and malignant tissues alike. In benign glands, basal cells were
labelled (Fig. 1a), whereas secretory cells were negative. In
neoplastic cells of HGPIN, TRPM4 showed stronger staining,
as Fig. 1b illustrates. Epithelia of invasive tumours showed the
highest degree of TRMP4 immunoreactivity. In the stroma,
immunostaining of smooth muscle cells was noted but not
semi-quantitatively evaluated.
Table 1 Demographic and clinical characteristics of 614 men who
underwent radical prostatectomy
Study
population
n=614
Age, years, median (range); n=614 62 (43–74)
Preoperative PSA, ng/ml, median (range); n=606 7.2 (0.8–39.0)
RP specimen Gleason score, no. (%); n=614
GS 6 219 (35.7)
GS 7 287 (46.7)
GS 8–10 108 (17.6)
Pathological tumour stage, no. (%); n=614
pT2 426 (69.4)
pT3 / pT4 188 (30.6)
Tumour in resection margin, no. (%); n=612
No (R-) 444 (72.5)
Yes (R+) 168 (27.5)
Preoperative hormonal therapy, no. (%); n=612
No 569 (93.0)
Yes 43 (7.0)
GS Gleason score, PSA prostate specific antigen, RP radical
prostatectomy
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Interobserver variation in TRPM4 intensity scoring
All 614 patients had valid TRPM4 intensity scores for
benign and cancerous tissue cores from both observers,
whereas 386 patients had two valid PIN TRPM4 inten-
sity scores. The interobserver concordance was 89.3,
91.5 and 86.0 % for benign, PIN and tumour TRPM4
intensity, respectively, corresponding to linear weighted
Kappa values of 0.566 (95 % CI 0.513–0.620), 0.789
(95 % CI 0.703–0.875) and 0.744 (95 % CI 0.682–
0.806) (Table 2). When H-scores were divided into four
groups, the concordance between the observers was
60.1 % corresponding to a linear weighted Kappa value
of 0.541 (95 % CI 0.489–0.592). There was a signifi-
cant and strong correlation between the two H-scores
when analysed on a continuous scale (Pearson’s corre-
lation coefficient=0.775, p<0.001).
TRPM4 protein expression in prostate cancer
Demographics and tumour characteristics of the patient pop-
ulation has previously been published [16] and are listed in
Table 1. In total, 43 patients (7.0 %) had received
gonadotropin-releasing hormone analogues before surgery at
the discretion of the referring urologist. Median time of treat-
ment was 4 weeks (range 2–16 weeks).
The predominant TRPM4 intensity was 1+ for benign
glands (84.4–89.3 %), PIN (73.4–76.4 %) and PCa glands
(63.0–66.8 %) for both observers (Figs. 1 and 2). However,
statistically significantly higher TRPM4 staining intensity was
found in PCa glands compared to benign tissue and PIN (chi-
square test for trend 50.81 and 126.54, respectively; 1 df; both
p<0.001). In cancerous glands, a predominant TRPM4 inten-
sity of 2+ and 3+ was found in 25.6–30.8 and 1.6–2.0 %,
respectively. Reflecting that the predominant TRPM4
Fig. 1 TRPM4
Immunohistochemistry in
prostate tissues. a TMPM4 is only
very weakly expressed in
secretory epithelium of benign
glands, whereas basal cells show
a weak to moderate labelling. b
Secretory epithelium of high
grade PIN glands often shows an
upregulation of TRPM4 staining.
c Prostate carcinoma with
Gleason Score 3+3=6 without
TRPM4 expression. Adjacent
myocytes of the stroma serve as
an internal positive control. d–f
Prostate cancer with weak (d),
moderate (e) or strong (f) TRPM4
positivity
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intensity was 1+, the median H-score was 100 (range 0–300)
and 110 (range 5–290) for observers 1 and 2, respectively,
with interquartile ranges of 100 to 150 and 80 to 150.
No association between TRPM4 expression and patient or
tumour characteristics (age, PSA, GS, pathological tumour
stage, and resection margin status) was found (Table 3).
TRPM4 protein expression and biochemical recurrence
PSA relapse-free survival time was available for 576 patients
(93.8 %). When dichotomising patients into ‘TRPM4
overexpressed’ vs. ‘TRPM4 not overexpressed’, there was
no significant difference between the two groups in terms of
risk of BR for the two observers (log-rank: p=0.05 and p=
0.66, respectively) (Supplementary Fig. S2a + b). Although
only statistically significant for observer 2, patients with ‘high
staining intensity’ had an increased risk of BR compared to
patients with ‘low staining intensity’ (log-rank: p=0.061 and
p=0.015, respectively) (Supplementary Fig. S2c + d).
A combined three-tiered variable was created representing
intrapersonal and interpersonal differences in TRPM4 expres-
sion. Patients were characterised as either ‘TRPM4 not
overexpressed and H-score below median’, or ‘TRPM4
overexpressed or H-score equal to or above median’, or
‘TRPM4 overexpressed and H-score equal to or above medi-
an’. On the records of observer 1, the groups separated into
three different courses of BR (log-rank: p=0.043), with pa-
tients characterised as ‘TRPM4 overexpressed and H-score
equal to or above median’ having the shortest BR free survival
(Fig. 3a). For observer 2, the ‘TRPM4 not overexpressed and
H-score below median’ group showed the best BR free sur-
vival (Fig. 3b), whereas the two other groups overlapped.
Correspondingly, no significant difference in disease course
was observed between the groups (log-rank: p=0.15).
Table 2 Interobserver agreement on immunohistochemical staining intensity of TRPM4
Benign TMA cores
Observer 2
0 1+ 2+ 3+ Patients eligible Concordance Weighted Kappa
n=614 89.3 % 0.566
Observer 1 0 20 3 0 0 (95 % CI 0.513–0.620)
1+ 36 500 12 0
2+ 0 15 28 0
3+ 0 0 0 0
PIN TMA cores
Observer 2
0 1+ 2+ 3+ Patients eligible Concordance Weighted Kappa
n=386 91.5 % 0.789
Observer 1 0 6 3 0 0 (95 % CI 0.703–0.875)
1+ 0 276 23 0
2+ 0 6 68 0
3+ 0 0 1 3
PCa TMA cores
Observer 2
0 1+ 2+ 3+ Patients eligible Concordance Weighted Kappa
n=614 86.0 % 0.744
Observer 1 0 26 10 1 0 (95 % CI 0.682–0.806)
1+ 0 359 51 0
2+ 0 18 135 4
3+ 0 0 2 8
PCa TMA cores–H-scores
Observer 2
0–50 51–100 101–150 151–300 Patients eligible Concordance Weighted Kappa
Observer 1 0–50 35 35 11 0 n=614 60.1 % 0.541
51–100 8 170 102 24 (95 % CI 0.489–0.592)
101–150 1 12 94 38
151–300 0 0 14 70
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TRPM4 was entered into two univariate and multiple Cox
proportional hazard regression models (model A and B) using
the individual TRPM4 sum scores for observer 1 and 2, re-
spectively. In both models, TRPM4 overexpression in combi-
nation with high staining intensity (i.e. TRPM4 overexpressed
in PCa compared with benign tissue combined with an H-
score equal to or above median) was associated with an in-
creased risk of BR (Table 4). This remained statistically sig-
nificant after adjusting for age, PSA, GS, pathological tumour
stage, surgical margins and prior hormonal treatment (model
A: HR 2.62; 95% CI 1.26–5.42; p=0.010; model B: HR 1.79;
95 % CI 1.06–3.04; p=0.030).
Discussion
This is the first report on TRPM4 protein expression in pros-
tate tissues using a large, well-characterised cohort of PCa
patients who have undergone RP. Our group has previously
shown that TRPM4 mRNA is among the top upregulated
transcripts in PCa [14], which is in line with other profiling
studies [18–20]. In the present paper, we used IHC to detect
TRPM4 protein and found that it is commonly expressed in
prostatic tissue. Protein expression was predominantly low,
although we demonstrated a significant trend for higher semi-
quantitative expression levels in PCa tissue compared to be-
nign and PIN glands. Although high TRPM4 expression as
such was not found to be associated with BR, the combination
of having high TRPM4 in PCa compared to matched benign
tissue with an H-score equal to or above median appeared to
be a strong predictive marker for BR. This corresponded to a
1.8–2.6-fold increased risk of BR after RP when compared to
patients without high TRPM4 expression and a low H-score.
Interestingly, we found no associations between TRPM4 ex-
pression and tumour characteristics, indicating that TRPM4 is
an independent prognostic marker. This needs to be verified in
future studies to clarify if TRPM4 might be a useful candidate
as prognostic test for prostate cancer, which clearly cannot be
based on a single retrospective study.
The TRPM4 protein consists of six transmembrane
domains and forms a nonselective cation channel after
assembly of four subunits upon activation, although the
stoichiometry is not yet fully known (reviewed in [12]).
The channel is activated by Ca2+ [21–23], has the
highest permeability for Na+ and K+, and is practically
impermeable to Ca2+ and Mg2+ [21, 23, 24]. It has pre-
viously been demonstrated that TRPM4 mRNA is widely
expressed in numerous types of tissue, the highest
mRNA transcript levels being found in the prostate and
the intestines [13]. Whereas the physiological function of
TRPM4 in the prostate is unknown, it is involved in such
diverse functions as depolarisation of vascular smooth
muscle cells [25], regulation of sinus rhythm of the heart
[26] and the process of cell death through Na+ influx
[27]. Furthermore, TRPM4 expression is upregulated in
an aggressive form of large B-cell non-Hodgkin lympho-
ma [28], and high expression has been found to correlate
with tumour progression and metastatic disease [18, 28].
In a recent study by Armisén et al., knockdown of TRPM4
with shRNA in HeLa cervical cancer cells was shown to signif-
icantly decrease proliferation, increase the fraction of cells in the
G1 phase of the cell cycle and decrease the fraction of cells
Fig. 2 TRPM4 expression in
prostate tissues at protein level.
Illustration of the progression of
TRPM4 expression from normal
tissue through PIN to invasive
carcinoma.
Immunohistochemical data from
observer 1 (left-most columns)
and observer 2 (right-most
columns)
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entering the S phase [15]. The authors further demonstrated that
knockdown of TRPM4 results in decreased expression of cyclin
D1, which is essential for the transition from G1 to S phase,
decreased expression of survivin, a protein involved in progres-
sion of mitosis and resistance to apoptosis, as well as a decreased
expression of β-catenin. In the absence of Wnt signalling, cyto-
plasmic β-catenin is phosphorylated by glycogen synthase ki-
nase 3β for degradation, whereasWnt signalling promotes trans-
location ofβ-catenin to the nucleus, which transactivates various
genes associated with proliferation and cell survival (reviewed in
[29, 30]). Indeed, Armisén et al. found thatβ-catenin is primarily
located in the cytoplasm after TRPM4 knockdown, compared to
its nuclear location in TRPM4 expressing HeLa cells. The au-
thors conclude that TRPM4 exerts its effects through inhibition
of degradation of β-catenin, leading to nuclear translocation and
increased cell proliferation [15]. In line with our results, this
suggests that a high level of TRPM4 in a cancer is associated
with a more aggressive course.
Most changes involving TRP proteins is caused by
increased or decreased expression of the normal protein
rather than mutations, and several members of the TRP
superfamily show altered expression in cancer cells [11].
Previous studies on PCa have mainly focused on
TRPM8 and TRPV6. Although the published results
are conflicting, significantly higher expression levels of
TRPM8 mRNA have been found in PCa in comparison
to benign tissue [31]. However, higher TRPM8 levels
were found to be inversely correlated to GS and tumour
stage, although not statistically significant [32].
Additionally, low levels of TRPM8 mRNA expression
were associated with a significant shorter time to BR
following RP [33]. Hence, it seems as if expression
level of TRPM8 is higher in PCa compared to benign
tissue, but lower in aggressive PCa. For TRPV6, normal
epithelial cells and BPH tissue show mRNA expression,
but interestingly, a higher expression level is found in
PCa tissue with a positive correlation with GS and path-
ological tumour stage [34, 35].
The present study has several limitations. First, we used BR
as the endpoint in the Kaplan-Meier and the Cox proportional
Table 3 Demographic and clinical characteristics of 614 men who underwent radical prostatectomy stratified on TRPM4 staining intensity
Observer 1 Low staining intensity
n = 124
High staining intensity
n = 490
p – value*
Age, years, median (range) 63 (45 – 73) 62 (43 – 74) 0.74
Preoperative PSA, ng/ml, median (range) 7.3 (2.4 – 30.4) 7.2 (0.8 – 39.0) 0.20cxx
RP specimen Gleason score, no. (%) 0.58
GS 6 40 (32.3) 179 (36.5)
GS 7 63 (50.8) 224 (45.7)
GS 8 – 10 21 (16.9) 87 (17.8)
Pathological tumour stage, no. (%) 0.27
pT2 81 (65.3) 345 (70.4)
pT3 / pT4 43 (34.7) 145 (29.6)
Tumour in resection margin, no. (%) 0.86
No (R-) 90 (73.2) 354 (72.4)
Yes (R+) 33 (26.8) 135 (27.6)
Observer 2 Low staining intensity
n = 292
High staining intensity
n = 322
Age, years, median (range) 63 (43 – 73) 62 (43 – 74) 0.99
Preoperative PSA, ng/ml, median (range) 7.1 (1.0 – 39.0) 7.3 (0.8 – 38.0) 0.82
RP specimen Gleason score, no. (%) 0.32
GS 6 112 (38.4) 107 (33.2)
GS 7 134 (45.9) 153 (47.5)
GS 8 – 10 46 (15.8) 62 (19.3)
Pathological tumour stage, no. (%) 0.67
pT2 205 (70.2) 221 (68.6)
pT3 / pT4 87 (29.8) 101 (31.4)
Tumour in resection margin, no. (%) 0.40
No (R-) 215 (74.1) 229 (71.1)
Yes (R+) 75 (25.9) 93 (28.9)
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hazard regression analyses. Although BR is a widely used
surrogate endpoint, it is well-known that a large proportion
of patients will not develop symptoms, metastasis let alone
PCa-related death even 10–15 years after BR, even if they
do not receive adjuvant or salvage therapy [36]. Secondly, in
most patients, PCa is a multifocal disease, and both intrafocal
and interfocal heterogeneity are critical issues and limitations
when studying tissue biomarkers, i.e. the accuracy of the IHC
results might be limited by variations in expression patterns
within and between tumour foci. Indeed, intrafocal and
interfocal staining heterogeneity for TRPM4 was observed
for up to 97% of the patients in the present study. To minimise
the impact of this heterogeneity, we used two TMA cores per
patient reflecting the primary and secondary Gleason pattern,
respectively, and calculated an H-score for each patient. It
might be argued, however, that two cores is insufficient to
fully elucidate heterogeneity [37]. Thirdly, semi-quantitative
IHC grading will inherently result in interobserver variation
[38]. Before introducing a new biomarker, it is essential to
acknowledge this drawback and moreover comprehend that
semi-quantitative grading is affected by subjectivity and in-
deed is only semi-quantitative. TRPM4 expression is not spe-
cific to epithelial cells but was also observed in stromal cells,
which can impede accurate reading and might negatively
Fig. 3 Kaplan-Meier estimated
biochemical recurrence free
survival curves for 576 patients
with available biochemical
follow-up data. a Patients are
stratified into three groups
according to observer 1’s records
on TRPM4 overexpression in
PCa compared to benign tissue
and H-scores. b Patients are
stratified into three groups
according to observer 2’s records
on TRPM4 overexpression in
PCa compared to benign tissue
and H-scores. BR-free survival
biochemical recurrence free
survival
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Table 4 Univariate and multiple Cox proportional hazard regression models for risk of biochemical recurrence after radical prostatectomy
Univariate analysis Multiple analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Model A
Age, 5 year change 0.89 (0.75-1.06) 0.20 0.84 (0.70-1.00) 0.055
PSA, 2-fold change 1.55 (1.17-2.06) 0.002 1.21 (0.91-1.60) 0.20
Gleason score
GS 6 1 (ref) 1 (ref)
GS 7 2.61 (1.42-4.77) 0.002 2.16 (1.15-4.08) 0.017
GS 8 – 10 6.62 (3.58-12.21) <0.001 3.16 (1.56-6.40) <0.001
Pathological tumour stage
pT2 1 (ref) 1 (ref)
pT3 / pT4 4.62 (3.02-7.06) <0.001 3.18 (1.94-5.21) <0.001
Tumour in resection margin
No 1 (ref) 1 (ref)
Yes 2.90 (1.93-4.36) <0.001 1.39 (0.86-2.23) 0.18
Preoperative hormonal therapy
No 1 (ref) 1 (ref)
Yes 1.59 (0.82-3.06) 0.17 1.38 (0.71-2.67) 0.34
TRPM4 expression and staining intensity
Not overexpressed and Low 1 (ref) 1 (ref)
Overexpressed or High 1.67 (0.85-3.27) 0.14 1.57 (0.79-3.12) 0.20
Overexpressed and High 2.38 (1.16-4.87) 0.017 2.62 (1.26-5.42) 0.010
Model B
Age, 5 year change 0.89 (0.75-1.06) 0.20 0.84 (0.70-1.00) 0.053
PSA, 2-fold change 1.55 (1.17-2.06) 0.002 1.20 (0.90-1.58) 0.21
Gleason score
GS 6 1 (ref) 1 (ref)
GS 7 2.61 (1.42-4.77) 0.002 2.11 (1.12-3.97) 0.022
GS 8 – 10 6.62 (3.58-12.21) <0.001 3.11 (1.54-6.26) 0.002
Pathological tumour stage
pT2 1 (ref) 1 (ref)
pT3 / pT4 4.62 (3.02-7.06) <0.001 3.26 (1.99-5.34) <0.001
Tumour in resection margin
No 1 (ref) 1 (ref)
Yes 2.90 (1.93-4.36) <0.001 1.39 (0.86-2.24) 0.18
Preoperative hormonal therapy
No 1 (ref) 1 (ref)
Yes 1.59 (0.82-3.06) 0.17 1.30 (0.67-2.52) 0.43
TRPM4 expression and staining intensity
Not overexpressed and Low 1 (ref) 1 (ref)
Overexpressed or High 1.55 (0.94-2.56) 0.085 1.42 (0.85-2.39) 0.18
Overexpressed and High 1.54 (0.93-2.55) 0.092 1.79 (1.06-3.04) 0.030
The two models include different evaluations of TRPM4 staining. Model A includes a combined variable representing both TRPM4 expression in PCa
compared to benign glands and the staining intensity for observer 1 (‘not overexpressed and low staining intensity’ vs. ‘overexpressed or high staining
intensity’ vs. ‘overexpressed and high staining intensity’). Model B includes the same combined variable for observer 2. High indicates TRPM4 staining
intensity equal to or above median H-score. Low indicates TRPM4 staining intensity bellow median H-score. Not overexpressed indicates staining
intensity in prostate cancer glands equal to or bellow benign glands. Overexpressed indicates staining intensity in prostate cancer glands above benign
glands
GS Gleason score, PSA prostate specific antigen, pT pathological tumour stage, ref reference
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influence interobserver agreement. In the present study, we
attempted to minimise the interobserver variation by creating
a TRPM4 scoring sheet, which resulted in approximately
90 % concordance rates indicating moderate to substantial
agreement according to the weighted kappa values [39].
Finally, this study lacks an independent validation cohort to
confirm the potential of TRPM4 as a prognostic biomarker,
which was, however, not the primary aim of this study.
Strengths of the present study are the large well-
characterised cohort of PCa patients, the long-term follow-
up and the inclusion of two independent observers.
TRP channels might be targets for management of cancer
using potent channel inhibitors or using the TRP proteins as
recognition sites for antibody-mediated toxic entry (reviewed
in [11]). While the channel might be a suitable and attractive
pharmacological target, blocking the channel might lead to
serious adverse events due to the wide distribution of the pro-
tein. Indeed, TRPM4 knockdown mice are characterised by
mild hypertension, increased risk of anaphylaxis and in-
creased risk of death in case of sepsis [12]. Thus, at the mo-
ment, TRPM4 does not seem to be a suitable pharmacological
target for management of PCa but seems to provide important
prognostic information in terms of risk of BR following RP.
Conclusions
We show that TRPM4 protein is widely expressed in benign
prostate tissue, PIN glands and cancerous glands with highest
scoring intensities in PCa. TRPM4 expression can be reliably
visualised using IHC staining with a commercial available poly-
clonal antibody. Moreover, the use of a scoring sheet resulted in
substantial agreement in TRPM4 staining intensity scores be-
tween two observers. Finally, the combination of TRPM4 over-
expression in PCa in comparison to matched benign glands and
an H-score equal to or above the median was independently
associated with an increased risk of BR following RP, which
warrants further study.
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